首页 > 市场调查报告书 > 医疗设备

e保健远距离医疗

市场调查报告书

商品编码

1643924

全球远距肿瘤学市场 - 2025-2032

Global Teleoncology Market - 2025-2032

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球远端肿瘤市场达到47亿美元，预计2032年将达到150.3亿美元，2024-2032年预测期间复合年增长率为15.7%。

远距肿瘤学是指远距医疗在肿瘤学中的应用，涉及透过虚拟平台提供诊断、治疗和监测等肿瘤学服务。远距肿瘤学使生活在偏远地区的患者能够以较低的成本获得准确的诊断、做出临床决策并获得精确的护理。远距肿瘤学减轻了偏远患者的经济负担，消除了经常去医院就诊的需要。

主要市场参与者在癌症护理中越来越多地采用和实施远距医疗以及现代医疗保健服务的技术进步，预计将在预测期内推动市场成长发挥至关重要的作用。

市场动态：

驱动程式和限制

远距医疗在癌症护理中的采用和实施不断增加

癌症护理中远距医疗的持续采用和实施是预测期内市场成长的一个主要因素。 COVID-19 大流行显然影响了向患者提供医疗保健的方式。远端监控、远距医疗和线上咨询已受到关注，其重要性在大流行后日益增长。大流行后，美国许多知名的癌症诊所已经开始虚拟咨询、远端监测和护理。

远距医疗实际上拉近了医生和患者的距离，并已成为向偏远或农村地区患者提供护理的主要媒介。

根据 USA Facts 报导，远距医疗的采用率在美国急剧上升。医疗保险受益人的远距医疗就诊次数从约 500 万增加到超过 5,300 万，大多数医生计划进一步实施远距医疗实践。

美国的几个癌症护理中心也开始提供虚拟服务，其中，线上咨询在农村地区的肿瘤患者中占据了很大份额。

远距医疗的实施也消除了旅行费用，减轻了农村患者的经济负担。例如，2023 年 JAMA 网路上发表的一项研究评估了与实施远距医疗相关的成本降低，报告称每次就诊平均节省 147 美元至 186 美元。

在预测期内，需求预计将持续上升，推动市场成长。

缺乏意识和技术差距

农村地区对远距肿瘤学的需求较高，居住在这些地区的患者群体是远距肿瘤学服务的主要目标。远端肿瘤学的实施与使用具有高速互联网连接的软体和现代电子设备有关。这可能对老年族群和存在技术差距的患者构成挑战。患者可能会觉得这个过程很麻烦，可能会犹豫是否采用这种新颖的照护方法，而更喜欢透过医师就诊的传统照护方式。

因此，儘管其他已开发地区的需求不断增长，但在世界某些地区，远距肿瘤学的采用仍受到质疑。此外，虚拟护理对癌症患者的选择有限。癌症患者必须接受频繁的筛检测试，以评估癌症的临床分期并检查治疗的预后。

虚拟地实现这一点的唯一方法是，如果患者访问最近的诊断中心，生成的放射影像将发送给虚拟地对患者进行治疗的相应医生。

由于农村地区缺乏适当的诊断设施，这一过程再次受到限制。有些患者可能会在整个过程中感到模糊。而且，各州的监管政策不同，采用的情况也可能因州而异。远距肿瘤学服务的报销政策和承保范围也可能有所不同。这可能会被动影响远距肿瘤学服务的采用。

所有这些因素都可能限制预测期内的市场成长。

Teleoncology refers to the application of telemedicine to oncology, which involves delivering oncology services such as diagnosis, treatment, and monitoring via virtual platforms. Teleoncology enables patients living in remote areas to get accurate diagnoses, make clinical decisions, and get precise care at lower costs. Teleoncology reduces the economic burden on remote patients, eliminating the need for frequent hospital visits.

The rising adoption and implementation of telemedicine in cancer care and technological advancements in modern healthcare services by major market players are expected to play a crucial role in driving market growth in the forecast period.

Market Dynamics: Drivers & Restraints

The Rising Adoption and Implementation of Telemedicine in Cancer Care

The rising adoption and implementation of telemedicine in cancer care is a major factor contributing to the market growth in the forecast period. The COVID-19 pandemic has clearly affected the way healthcare is delivered to patients. Remote monitoring, telemedicine, and online consultations have gained traction, and their importance is ever-growing post-pandemic. Post-pandemic many reputed cancer clinics across the U.S. have started virtual consultations, remote monitoring, and care.

Telemedicine has brought physicians and patients closer virtually, and it has become a major medium for care delivery to patients living in remote or rural areas.

According to USA Facts, the adoption of telehealth has risen drastically in the United States. Telehealth visits have increased from about 5 million to more than 53 million among Medicare recipients and the majority of physicians plan to implement telemedicine practices going further.

Several cancer care delivery centers in the U.S. have also initiated delivering their services virtually, and among these services, online consultations have a major share for oncology patients living in rural areas.

The implementation of telehealth has also reduced the financial burden imposed on rural patients by eliminating the cost of travel. For instance, a research study published in the JAMA network in 2023, which has evaluated the cost reductions associated with the implementation of telehealth has reported an average saving between US$147 to US$186 per visit.

In the forecast period, the demand is expected to continuously rise, fuelling the market growth.

Lack of Awareness and Technological Gaps

The need for Teleoncology is higher in rural areas and the patient population living in these parts is the major target for teleoncology services. The implementation of Teleoncology is linked with the use of software and modern electronic devices with high-speed internet connectivity. This may pose a challenge to the elderly population and patients with technological gaps. Patients may feel this process to be cumbersome and may hesitate to adopt this novel method of care, and rather prefer the traditional way of care through physician visits.

Hence the adoption of teleoncology becomes questionable in certain parts of the world, despite the growing demand in the other well-developed regions. Moreover, virtual care has limited options for cancer patients. Cancer patients must undergo frequent screening tests to assess the clinical stage of cancer and to check the prognosis of the treatment.

The only way this can be done virtually is if the patient visits the nearest diagnostic center, the radiology images generated will be sent to the corresponding physician who is addressing the patient virtually.

This process again is limited by the lack of proper diagnostic facilities in rural areas. Some patients may feel ambiguity in this entire process. Moreover, the regulatory policies vary from state to state, and the adoption may vary according to the state. The reimbursement policies and extent of coverage for Teleoncology services may also vary. This may passively impact the adoption of teleoncology services.

All these factors may restrain the market growth in the forecast period.

Segment Analysis

The global teleoncology market is segmented based on component, cancer type, application, and region.

Breast cancer is the cancer type segment that is expected to dominate the market.

Among different cancers that are affecting patients, breast cancer is one of the most prevalent cancers.

For instance, As per the recent statistics published by the Global Cancer Observatory, in 2022, there are approximately 2.3 million new breast cancer cases reported across the world. Ranking among the top most incident cancer cases. It is estimated that in 2025, the number of breast cancer cases incidence will rise to 2.5 million, and in 2030, the incidence will reach 2.7 million cases. This alarming rise in breast cancer is a major contributing factor to its dominance in the teleoncology market.

As the number of patients with breast cancer is higher among other cancers, the patient population opting for teleoncology services is also expected to be higher. For instance, according to a study published in Nature Journal in 2023, the implementation of telemedicine is majorly recorded for breast cancer followed by lung cancer, head, and neck cancers, brain cancer, and others, and among the telemedicine, teleconsultation was the most commonly deployed application with a share of 60%.

Moreover, due to care disparities among urban and rural populations, breast cancer patients in rural areas have higher mortality as compared to urban breast cancer patients. The disparities arise from a lack of care physicians, advanced diagnostic facilities, and a lower rate of early cancer diagnosis. For instance, a recent study published in the National Center for Biotechnology Information in 2021, has stated that the 10-year risk of breast cancer mortality is higher among rural population i.e., 17.1%, which is higher than that of mortality of breast cancer patients living in metropolitan areas which is 14.6%.

The implementation of teleoncology services and the launch of remote digitalized diagnostic equipment in rural areas will provide an opportunity to increase the survival rate, and also reduce the financial burden imposed due to frequent physician visits for breast cancer patients.

Geographical Analysis

North America is expected to hold a significant share of the teleoncology market.

North America currently holds a significant market share in the teleoncology market due to various factors including, the advanced healthcare infrastructure, technologically advanced states, high awareness of telemedicine, and the rising prevalence of cancer. For instance, as per the International Agency for Research on Cancer projections, nearly 2.60 million new cancer cases were reported in North America, and by 2040, the incidence is expected to reach 3.60 million. This rising prevalence combined with the advanced healthcare landscape positions North America as the market leader in the global teleoncology market.

The region has higher investments in telehealth platforms to significantly improve patient access to medical care. Moreover, governments in North America are proactively supporting the integration of telemedicine, encompassing teleoncology, through diverse policies and initiatives. One significant example is the Centers for Medicare & Medicaid Services (CMS) in the U.S., which has broadened its reimbursement policies for telehealth services. This expansion includes teleoncology, thereby enhancing patient accessibility to these advanced healthcare services.

Competitive Landscape

The major global players in the teleoncology market are Teladoc Health, Inc., American Well, Moffitt Cancer Center, Eagle Telemedicine., Intermountain Health, Klara Technologies, Inc., DocPanel Technologies, Inc., OurExpertDoc, Cancerdocs and OncoHealth. among others.

Emerging Players

The emerging players in the teleoncology market include Proto Inc., Shemha Health, Belong. Life, among others

Key Developments

In September 2024, Proto Inc. in collaboration with West Cancer Center & Research Institute launched the first holographic doctor-patient visits at UC Berkeley's forum. This innovation provides patients living in remote areas access to specialized oncology care.
In April 2023, Shemha Health launched a new Telemedicine platform called PrOPA (Precision Oncology Patient Advice). PrOPA is a large-scale solution designed to provide virtual end-to-end solutions for cancer patients ranging from initial diagnostics to treatment. In PrOPA, top-selected healthcare professionals consult to discuss and formulate specific guidelines for diagnosis, treatment, and patient monitoring.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global teleoncology market report would provide approximately 62 tables, 57 figures, and 195 pages.

Target Audience 2023

Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Component
3.2. Snippet by Cancer Type
3.3. Snippet by Application
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. The Rising Adoption and Implementation of Telemedicine in Cancer Care
- 4.1.3. Technological Advancements in Remote Patient Monitoring
4.2. Restraints
- 4.2.1. Lack of Awareness and Technological Gaps
- 4.2.2. XX
4.3. Opportunities
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Patent Analysis
5.4. Regulatory Analysis
5.5. Technology and Trend Analysis

6. By Component

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 6.1.2. Market Attractiveness Index, By Component
6.2. Software*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hardware
6.4. Services

7. By Cancer Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Breast Cancer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lung Cancer
7.4. Colorectal Cancer
7.5. Prostate Cancer
7.6. Bladder Cancer
7.7. Liver Cancer
7.8. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Remote Patient Monitoring*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Medical Second Opinions
8.4. Patient Consultations
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

11.1. Teladoc Health, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.3. Financial Overview
  - 11.1.3.1. Company Revenue's
  - 11.1.3.2. Geographical Revenue Shares
  - 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
  - 11.1.4.1. Mergers & Acquisitions
  - 11.1.4.2. Key Product Development Activities
  - 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
11.2. American Well
11.3. Moffitt Cancer Center
11.4. Eagle Telemedicine.
11.5. Intermountain Health
11.6. Klara Technologies, Inc.
11.7. DocPanel Technologies, Inc.
11.8. OurExpertDoc
11.9. Cancerdocs
11.10. OncoHealth.
Similar data will be provided for each market player.